A multimodal treatment approach including high-dose chemotherapy in very advanced gastric cancer: Evidence for control of metastatic disease

Bone Marrow Transplantation

Volumn 32, Issue 7, 2003, Pages 665-671

  Reichle, Albrecht ^a   Bolder, U ^a   Bataille, F ^a   Messmann, H ^a   Wagner, H ^a   Zaiss, M ^a   Wild, P ^a   Hofstadter F ^a   Andreesen, R ^a   Jauch, K W ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Advanced gastric cancer; Multimodal treatment; Neoadjuvant chemotherapy

Indexed keywords

AMPHOTERICIN; CARMUSTINE; CISPLATIN; DOXORUBICIN; ETOPOSIDE; MITOMYCIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER GROWTH; CANCER REGRESSION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; ELECTROCORTICOGRAPHY; EVIDENCE BASED MEDICINE; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS C; HUMAN; INFECTION; LAPAROSCOPY; LIVER TOXICITY; MALE; MULTIMODALITY CANCER THERAPY; NEUTROPENIA; PANCYTOPENIA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; STEM CELL MOBILIZATION; STOMACH CANCER;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FEMALE; GASTRECTOMY; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 12444275670     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704203     Document Type: Article

References (25)

1. Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on cancer staging, proximal disease, and the "different disease" hypothesis. Cancer 2000; 88: 921-932.
2. Kelsen D, Atiq OT, Saltz L et al. FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol 1992; 10: 541-548.
3. Webb A, Cunningham D, Scarffe JH et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15: 261-267.
4. Vanhoefer U, Rougier P, Wilke H et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000;18: 2648-2657.
5. Ajani JA, Mansfield PF, Lynch PM et al. Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma. J Clin Oncol 1999; 17: 2403-2411.
6. Fink U, Schuhmacher C, Stein HJ et al. Preoperative chemotherapy for stage III-IV gastric carcinoma: feasibility, response and outcome after complete resection. Br J Surg 1995; 82: 1248-1252.
7. Wilke H, Stahl M, Fink U et al. Preoperative chemotherapy for unresectable gastric cancer. World J Surg 1995; 19: 210-215.
8. Plukker JT, Mulder NH, Sleijfer DT et al. Chemotherapy and surgery for locally advanced cancer of the cardia and fundus: phase II study with methotrexate and 5-fluorouracil. Br J Surg 1991; 78: 955-958.
9. Melcher AA, Mort D, Maughan TS. Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) as neoadjuvant chemotherapy in gastro-oesophageal cancer. Br J Cancer 1996; 74: 1651-1654.
10. Schuhmacher CP, Fink U, Becker K et al. Neoadjuvant therapy for patients with locally advanced gastric carcinoma with etoposide, doxorubicin, and cisplatinum. Closing results after 5 years of follow-up. Cancer 2001; 91: 918-927.
11. Lowy AM, Feig BW, Janjan N et al. A pilot study of preoperative chemo-radiotherapy for resectable gastric cancer. Ann Surg Oncol 2001; 8: 519-524.
12. Yonemura Y, Kinoshita K, Fujimura T et al. Correlation of the histological effects and survival after neoadjuvant chemotherapy on gastric cancer patients. Hepatogastroenterology 1996; 43: 1260-1272.
13. Cascinu S, Ficarelli R, Safi MA et al. A phase I study of paclitaxel and 5-fluorouracil in advanced gastric cancer. Eur J Cancer 1997; 3: 1699-1702.
14. Bokemeyer C, Lampe CS, Clemens MR et al. A phase II trial of paclitaxel and weekly 24h infusion of 5-fluorouracil/folinic acid in patients with advanced gastric cancer. Anticancer Drugs 1997; 8: 396-399.
15. Kollmannsberger C, Quietzsch D, Haag C et al. A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br J Cancer 2000; 83: 458-462.
16. Shirao K, Shimada Y, Kondo H et al. Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. J Clin Oncol 1997; 15: 921-927.
17. Berdel WE, Heldmann T, Thiel E. Long-term results of a phase-II-pilot trial on preoperative high-dose chemotherapy with stem cell rescue in patients with cancer of the upper gastrointestinal tract. Oncol Rep 2001;8: 341-342.
18. Roder JD, Bottcher K, Siewert JR et al. Prognostic factors in gastric carcinoma. Results of the German Gastric Carcinoma Study 1992. Cancer 1993; 72: 2089-2097.
19. Lowy AM, Mansfield PF, Leach SD et al. Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg 1999; 229: 303-308.
20. Siewert JR, Bottcher K, Stein HJ et al. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 1998; 228: 449-461.
21. Wilke H, Preusser P, Fink U et al. Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin. J Clin Oncol 1989; 7: 1318-1326.
22. Kelly S, Harris KM, Berry E et al. A systematic review of the staging performance of endoscopic ultrasound in gastrooesophageal carcinoma. Gut 2001; 49: 534-539.
23. Ozaki T, Flege S, Kevric M et al. Osteosarcoma of the pelvis: experience of the Cooperative Osteosarcoma Study Group. J Clin Oncol 2003; 21: 334-341.
24. Burstein HJ, Harris LN, Gelman R et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol 2003; 21: 46-53.
25. Walsh GL, Taylor GD, Nesbitt JC, Amato RJ. Intensive chemotherapy and radical resections for primary nonseminomatous mediastinal germ cell tumors. Ann Thorac Surg 2000; 69: 337-343.